LONA

LeonaBio Inc

4.84

Oct 23 • 3:59 PM ET -0.13 (-2.62%)

4.94

Aftermarket • 5:06 PM ET +0.10 (2.06%)

Healthcare Biotechnology USA Nano NASD

Peers: OLMA ARVN ATOS CLNN CELC COYA PMN RLAY GLSI INMB

| Held by: VTI SURI VXF IWC DFMC DCOR DFSU

Scroll to Statements

Index	-
Market Cap	45.59M
Enterprise Value	-4.90M
Income	-141.46M
Sales	0.00M
Book/sh	3.57
Cash/sh	5.42
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	Sep 18, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.36
P/C	0.89
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.01
Current Ratio	7.01
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-23.11
EPS next Y	-2.34
EPS next Q	-0.69
EPS this Y	88.52%
EPS next Y	17.46%
EPS next 5Y	58.52%
EPS past 3/5Y	0.86% -32.09%
Sales past 3/5Y	- -
EPS Y/Y TTM	-49.65%
Sales Y/Y TTM	-
EPS Q/Q	55.04%
Sales Q/Q	-
Earnings	Aug 14 AMC
EPS/Sales Surpr.	42.40% -

Insider Own	32.39%
Insider Trans	0.00%
Inst Own	56.73%
Inst Trans	13.46%
ROA	-306.05%
ROE	-431.39%
ROIC	-419.98%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.18%
SMA50	-23.79%
SMA200	-35.94%
Trades

Shs Outstand	9.42M
Shs Float	6.37M
Short Float	0.30%
Short Ratio	0.10
Short Interest	0.02M
52W High	14.21 -65.94%
52W Low	2.21 119.00%
Volatility	11.72% 21.66%
ATR (14)	0.73
RSI (14)	41.85
Beta	1.95
Rel Volume	0.18
Avg Volume	187.71K
Volume	33,796

Perf Week	-6.92%
Perf Month	-3.01%
Perf Quarter	-34.24%
Perf Half Y	-41.90%
Perf YTD	-36.06%
Perf Year	21.30%
Perf 3Y	-69.37%
Perf 5Y	-95.48%
Perf 10Y	-
Recom	1.00
Target Price	17.33
Prev Close	4.97
Price	4.84
Change %	-2.62%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform	$18
May-27-26	Initiated	Piper Sandler	Overweight	$20
Feb-26-26	Initiated	Cantor Fitzgerald	Overweight
Feb-19-26	Upgrade	Mizuho	Neutral → Outperform	$10
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30

Show Previous Ratings

Sep-03-26 07:00AM	LeonaBio to Participate in Cantor Global Healthcare Conference 2026 (GlobeNewswire)
Aug-17-26 08:26AM	LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances (InvestorsHub)
Aug-14-26 04:05PM	LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-12-26 07:00AM	LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer (GlobeNewswire)
Jun-04-26 07:00AM	LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit (GlobeNewswire)
07:00AM	Loading…
May-27-26 07:00AM	LeonaBio to Participate in Upcoming Medical and Industry Meetings in June (GlobeNewswire)
May-07-26 04:05PM	LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:20AM	LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. (GlobeNewswire)
Apr-23-26 04:05PM	LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer (GlobeNewswire) -5.90%
Apr-21-26 07:00AM	Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data (GlobeNewswire)
Mar-26-26 05:10PM	LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.20% -7.33%
Feb-03-26 07:00AM	LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer (GlobeNewswire)
Jan-09-26 07:00AM	Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" (GlobeNewswire) -6.12%
Dec-18-25 07:02AM	Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million (GlobeNewswire) +62.52%
Nov-06-25 04:05PM	Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:00AM	Loading…
Sep-11-25 09:00AM	Athira Pharma Announces Reverse Stock Split (GlobeNewswire)
Aug-14-25 07:00AM	Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 (GlobeNewswire)
Aug-07-25 04:05PM	Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.95%
May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
04:01PM	Loading…
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Litton Mark James	PRESIDENT and CEO	Mar 03 '26	Option Exercise	0.00	22,254	0	63,082	Mar 05 07:14 PM
Litton Mark James	PRESIDENT and CEO	Mar 04 '26	Sale	5.37	5,156	27,688	57,926	Mar 05 07:14 PM
Renninger Robert	CHIEF FINANCIAL OFFICER	Mar 03 '26	Option Exercise	0.00	3,900	0	16,757	Mar 05 07:10 PM
Renninger Robert	CHIEF FINANCIAL OFFICER	Mar 04 '26	Sale	5.37	906	4,865	15,851	Mar 05 07:10 PM
Worthington Mark	GENERAL COUNSEL and CCO	Mar 03 '26	Option Exercise	0.00	5,726	0	19,704	Mar 05 07:06 PM
Worthington Mark	GENERAL COUNSEL and CCO	Mar 04 '26	Sale	5.37	1,328	7,131	18,376	Mar 05 07:06 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Mar 03 '26	Option Exercise	0.00	5,856	0	26,537	Mar 05 07:02 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Mar 04 '26	Sale	5.37	1,359	7,298	25,178	Mar 05 07:02 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Mar 03 '26	Option Exercise	0.00	7,418	0	17,607	Mar 05 06:59 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Mar 04 '26	Sale	5.37	1,720	9,236	15,887	Mar 05 06:59 PM
Mark James Litton	Officer	Mar 04 '26	Proposed Sale	5.36	5,156	27,662		Mar 04 07:47 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '25	Option Exercise	0.00	4,667	0	11,833	Jan 05 07:52 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '26	Sale	6.88	1,644	11,311	10,189	Jan 05 07:52 PM
Litton Mark James	President and CEO	Dec 31 '25	Option Exercise	0.00	10,834	0	43,414	Jan 05 07:51 PM
Litton Mark James	President and CEO	Jan 02 '26	Sale	6.88	2,586	17,792	40,828	Jan 05 07:51 PM
Renninger Robert	Chief Financial Officer	Dec 31 '25	Option Exercise	0.00	1,236	0	13,154	Jan 05 07:50 PM
Renninger Robert	Chief Financial Officer	Jan 02 '26	Sale	6.88	297	2,043	12,857	Jan 05 07:50 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '25	Option Exercise	0.00	3,667	0	21,557	Jan 05 07:50 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '26	Sale	6.88	876	6,027	20,681	Jan 05 07:50 PM
Worthington Mark	General Counsel and CCO	Dec 31 '25	Option Exercise	0.00	3,667	0	14,854	Jan 05 07:49 PM
Worthington Mark	General Counsel and CCO	Jan 02 '26	Sale	6.88	876	6,027	13,978	Jan 05 07:49 PM

LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Ph.D.Dr. Mark J. Litton M.B.A.

General CounselMr. Mark F. Worthington J.D.

Chief Medical OfficerDr. Javier San Martin M.D.

Chief Financial OfficerMr. Robert Renninger

Chief Scientific OfficerDr. Kevin Church Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LONA

LeonaBio Inc

Upgrade your Finviz experience